Clinical Trial Update: Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders [Phase 2]

View source ↗

Summary

Phase 2 double-blind trial of buspirone for treating anxiety in youth with Autism Spectrum Disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Autism Spectrum Disorder

Drugs mentioned

• Buspirone (buspirone)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Autism Spectrum Disorder (ASD) | Phase 2 | Status: WITHDRAWN